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Current retroviral vectors based on murine leukemia virus (MuLV) are unable to efficiently transduce nondividing cells.
Lentiviruses, such as the human immunodeficiency virus 1 (HIV-1) are efficient at transducing nondividing, growth-arrested,
and post-mitotic cells, but due to complex safety considerations, they may have limited potential for human clinical gene
transfer. For this reason, alternatives to MuLV and HIV-1 vectors need to be explored. In this paper, we have found that simian
foamy virus vector (SFV-1) containing a CMV-LacZ expression cassette is able to efficiently transduce multiple cell types of
various species that include epithelial, lymphoid, and hematopoietic-derived human cell lines and fibroblast cell lines of
several species. Previously it was reported that foamy virus replication is cell cycle dependent (P. D. Bieniasz, R. A. Weiss,
and M. O. McClure, 1995. J. Virol. 69, 7295–7299). However, others studies demonstrated nuclear import of viral DNA in
arrested cells (A. Saibi, F. Puvion-Dutilleul, M. Schmid, J. Peries, and H. d. The 1997. J. Virol. 71, 1155–1161). Here, we show
efficient LacZ transduction by SFV-1 vectors in several chemically arrested cell lines and terminally differentiated human
neurons. SFV-1 vector can transduce cell lines arrested in G1/S phase of the cell cycle by aphidicolin treatment with similar
efficiencies to that of dividing cells. The terminally differentiated human neural cell line, NT2N, was transduced with 30–50%
efficiency, corroborating our data obtained with the arrested cell lines. To further examine whether the SFV-1 vector can
efficiently deliver a gene into clinically important cells for gene therapy, we transduced primary human peripheral blood cells
(PBLs) in the presence and absence of phytohemagglutanin (PHA) stimulation. We observed 81% transduction efficiency in
non-stimulated PBLs and 87% in PHA-stimulated PBLs with vector infection carried out twice in 8 hours intervals at a
multiplicity of infection of 1. Together, these data indicate that SFV-1 based retroviral vectors may provide a safe, efficient
alternative to current onco- and lentiviral vectors for gene transfer in cells from a broad spectrum of lineages across species
boundaries. © 2001 Academic PressINTRODUCTION
Retroviruses provide an efficient means for stably in-
troducing foreign DNA into the cell genome of a broad
spectrum of target cells (Mulligan, 1993). The life cycle of
retroviruses involves integration of the genome into the
host DNA, replication, and transmission to the progeny of
infected cells (Coffin et al., 1997). For this reason, retro-
virus-mediated gene therapy is a promising approach for
the treatment of human disease. Most retroviral vector
systems use some components of murine leukemia virus
(MuLV) (Miller et al., 1993; Vile and Rusell, 1995). How-
ever, MuLV replication requires at least one round of cell
division for proviral integration into target cells (Miller et
al., 1990; Roe et al., 1993; Springett et al., 1989). Thus,
these vectors are inadequate to stably transduce nondi-
viding and/or terminally differentiated cells, which se-
verely restricts their potential utility for clinical gene
transfer. In contrast, terminally differentiated macro-1 To whom reprint requests should be addressed. Fax: (352)-392-
704. E-mail: mergiaa@mail.vetmed.ufl.edu.
243phages, mucosal dendritic cells, and quiescent T lym-
phocytes are non-proliferating targets of critical impor-
tance for transmission, propagation, and spread of the
human immunodeficiency virus (HIV) in the infected host
(Fauci, 1996; Levy, 1993). This feature allows vectors
based on HIV to transduce nondividing cells and inte-
grate their proviral DNA (Lewis et al., 1992; Lewis and
Emerman, 1994). However, HIV vectors for human gene
therapy are limited by safety concerns for patients and
remain a public health issue. Other lentivirus vectors
have a restricted host tropism and it is unclear whether
they infect human cells. This stumbling block for devel-
oping vectors based on animal lentiviruses has recently
been rectified by psuedotyping the system with vesicular
stomatitis virus envelope glycoprotein G (VSV-G) (Poe-
schla et al., 1998b). Nevertheless, the comparative safety
and efficacy of vectors based on non-primate lentiviruses
remain to be determined.
As an alternative to lentivirus vectors, foamy viruses
may provide a safe and efficient means of targeting
nondividing cells, satisfying current concerns with exist-
ing retrovirus vectors. Foamy viruses are found in many
0042-6822/01 $35.00
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244 MERGIA ET AL.mammalian species and appear to be ubiquitous. These
viruses can be propagated efficiently in various cell
types of several species (Mergia et al., 1996). Cultured
epithelial and fibroblast cells as well as lymphoid and
neural-originated cells support the growth of foamy vi-
ruses. Each foamy virus isolate can infect several mam-
malian species, and virus has been recovered from many
organs in these animals (Hooks and Detrick-Hooks,
1981). To date, no disease has been attributed to foamy
virus in naturally or experimentally infected animals (Flu-
gel, 1991; Mergia and Luciw, 1991; Weiss, 1988). Further-
more, animal caretakers accidentally infected with SFV
remain healthy (Heneine et al., 1998; Schweizer et al.,
1997). The facts that foamy viruses have a broad host
range, do not cause disease, and persist in infected
humans (Callahan et al., 1999; Heneine et al., 1998;
chweizer et al., 1997) make them an ideal vector system
or human disease gene therapy. Recently, SFV-1- and
uman foamy virus (HFV)-based vectors capable of gene
ransfer were developed (Mergia and Wu, 1998; Russell
nd Miller, 1996; Schmidt and Rethwilm, 1995; Wu et al.,
998). Similar to other retroviruses, the sequences within
he 59 untranslated leader region and the 59 end of the
ag gene are important cis-acting elements for foamy
irus vector construction (Wu et al., 1998). However,
oamy virus replication is unique and requires additional
eatures for vector construction. For example, a second
is-acting element that is critical for foamy virus vectors
s located at the 39 end of the pol gene (Erlwein et al.,
998; Heinkelein et al., 1998; Wu et al., 1998). The abso-
ute requirement of this sequence in the pol gene for
oamy virus vectors is novel among retroviruses, al-
hough its function in foamy virus replication remains to
e determined.
The ability of foamy virus vectors to transduce station-
ry cells remains controversial. Russell and Miller (1996)
emonstrated transduction of stationary phase human
ibroblasts by HFV vectors, albeit less efficiently than
ividing fibroblasts. In these studies, efficiency of gene
ransduction by HFV was higher than that of MuLV. Gene
ransfer with foamy virus vector in primate hematopoietic
ells also showed better transduction than that of MuLV
Hirata et al., 1996). In support of this, Saib et al. (1997)
ere able to demonstrate that foamy virus DNA can
nter the nucleus of G1/S-phase-arrested cells, although
o viral gene expression was observed. In contrast to
hese studies, others have reported that productive
oamy virus infection is cell cycle dependent (Bieniasz et
l., 1995). To determine whether a foamy virus vector
ould be developed for expression of transduced genes
n sationary as well as proliferating cells, we evaluated
n SFV-1 vector that we previously developed (Wu and
ergia, 1999) for transduction of G1/S phase-arrestedell lines and post-mitotic human neurons. In addition,
e evaluated the efficiency of SFV-1 vector in phytohe-magglutanin (PHA) stimulated and unstimulated human
peripheral blood cells (PBLs).
RESULTS
SFV-1 vector system
The construction of the SFV-1 vector plasmid pVC7-9 is
described elsewhere (Wu and Mergia, 1999). In pVC7-9,
the minimal human CMV promoter was fused to the
transcription start site located in the R region of the
59LTR to direct high-level vector transcription from 11 of
the SFV-1 genome (Fig. 1). This technique has been
shown to produce rapid, high-titer MuLV vector con-
structs by transient transfection (Naviaux et al., 1996).
The vector contains SFV-1 sequences from the beginning
of the R to the end of the pol gene, the PPT and the 39
LTR. To monitor for the efficiency of transduction, a LacZ
gene under the control of CMV promoter is placed be-
tween the pol gene and PPT. Packaging plasmid (pCG-
PETH) for SFV-1 vector is constructed by placing the
structural genes gag, pol, and env, and tas downstream
from the CMV promoter (Wu and Mergia, 1999). Splice
donor of the 59 SFV-1 is provided between CMV promoter
and the gag gene in pCGPETH. The SV40 poly A signal
sequence is supplied at the 39 end. SFV-1 vector was
produced by transient co-transfection of each of vector
plasmid pVC7-9 and packaging plasmid pCGPETH with
LipofectAMINE transfection reagent (Gibco-BRL).
Efficiency of SFV-1 vector in multiple cell lineages
Foamy viruses have a broad cell tropism and infect a
FIG. 1. Schematic representations of SFV-1 vector (pCV7-9) and
packaging construct (pCGPETH) used to generate SFV-1 vector socks.
The constructions of these plasmids were described previously (Wu
and Mergia, 1999). The provirus genome of SFV-1 is shown in the top
panel. The numbers represent the nucleotide positions in the proviral
genome. CMV is the promoter of the human cytomegalovirus immedi-
ate early gene.wide variety of cell types from different species. As a
result, foamy virus-based vectors are thought to be ideal
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245SAFE ALTERNATIVE FOR GENE TRANSFER IN CELLSfor gene delivery into cells of different lineages. To de-
termine the efficiency of SFV-1 vector transduction and to
verify that the replication-defective derivative vector con-
struct retained the cell tropism of the parental wild-type
virus, SFV-1 vector particles were tested for transduction
of fibroblasts, epithelial-, lymphoid-, neuronal-, and he-
matopoietic-derived cell lines, from human and non-hu-
man sources. Virus stocks were prepared by transfecting
the SFV-1 vector and packaging plasmid into 293T cells.
These cells gave the highest titer vector production
(#5 3 106/ml, data not shown) compared to all cell lines
isted in Table 1. We have previously shown, as with other
etroviral vector systems, transient high-titer vector can
e achieved in the SFV-1 system by replacing the U3
egion with the CMV promoter and transfecting 293 cells
Wu and Mergia, 1999). The 293T cells, derived from 293
arental cells, consistently gave enhanced vector pro-
uction compared to the parental cell line. SFV-1 vector
tock prepared in 293T cells was then used to infect cell
ines listed in Table 1 to determine the efficiency of SFV-1
ector transduction over broad host ranges. Target ad-
erent cells showed titers ranging from 5 3 105 (HeLa
ells) to 4.1 3 106 (293T), while 69% of the non-adherent
human T cell line (Hut-78) and 56% of the hematopoietic
line (K562) were transduced. These observations re-
vealed that our SFV-1 vector can efficiently transduce
cells of distinct cell lineages across different species
T
Transduction of Multiple Ce
Cell line Cell type
293T Human kidney fibroblast
293 Human kidney fibroblast
HeLa Human epithelial cell
HOS.CD4/CXCR4 Human osteosarcoma fibroblast
HOS.CD4/CCR5 Human osteosarcoma fibroblast
COS7 African green monkey kidney fibroblas
CRFK Crandell feline kidney fibroblast
Cf2Th Canine thymus fibroblast
Cell line Cell type
HuT78 Human T cell
K562 Human hematop
a Titers given as number of b-Gal-positive cells/ml of supernatant, an
uplicate 6 standard error of the means (SE).
b Relative transduction efficiency was calculated as SFV-1 titer on ea
efficiency of 293T cells 5 1.00 (100%).
c Data represent percent b-galactosidase-positive cells of total cell p
performed in triplicate.and suggest a potentially broad clinical application for
foamy virus vector-based gene therapy.SFV-1 vector in growth-arrested cells
Previous reports indicated that wild-type HFV, SFV-1,
and SFV-6 fail to establish productive infection in G1/S-
arrested cells, suggesting that foamy virus vector cannot
be utilized to deliver genes in nondividing cells (Bieniasz
et al., 1995). However, a subsequent report (Russell and
Miller, 1996) demonstrated HFV infection and replication
in stationary phase human fibroblasts. To determine
whether a foamy virus vector could indeed infect and
transduce nondividing cells, we tested our SFV-1 vector
in aphidicolin arrested cells (G1/S phase of the cell
cycle). Cells were transduced with MuLV or SFV-1 vector
after 24 h with or without aphidicolin exposure. Medium
was replenished daily with or without aphidicolin for an
additional 48 h prior to b-Gal assay. Transductions were
erformed in multiple cell types to verify that cellular
actors alone did not contribute to transduction efficiency
n arrested cells. Efficiency of transduction was calcu-
ated as a percentage of b-Gal positive cells in arrested
cells versus dividing cells. Consistent with previous re-
ports (Lewis and Emerman, 1994; Olsen, 1998; Poeschla
et al., 1998; Springett et al., 1989) the MuLV vector was
nefficient at transducing growth-arrested cells with ,1%
f the arrested cell population staining positive for b-Gal
in comparison to the transduction of dividing cells (Table
2). For the SFV-1 vector, transduction efficiencies in the
s by SFV-1 Vector, pCV7-9
Adherent cell lines
Titer 6 SE (31026
B-gal positive cells/ml)a
Relative
transduction efficiencyb
4.1 6 0.296 1.0
1.8 6 0.059 0.42
0.5 6 0.032 0.12
2.2 6 0.190 0.54
3.1 6 0.207 0.76
3.1 6 0.470 0.96
2.5 6 0.205 0.59
0.9 6 0.008 0.22
Suspension cell lines
Transduction efficiencyc
69.3 6 6.1%
56.4 6 4.3%
ulated based on three independent titration experiments performed in
divided by the titer obtained on the 293T cell line, where transduction
n 6 standard error of the means from three independent experimentsABLE 1
ll Type
t
oietic
d calc
ch cellG1/S phase-arrested 293T, CRFK, and HeLa cells were
98.5 6 26.8, 90.4 6 7.2, and 108 6 19.9% that of dividing
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246 MERGIA ET AL.cells, respectively. The reason for the higher transduc-
tion efficiency in comparison to the previous study with
HFV vector (Russell and Miller, 1996) is due to our high
titer SFV-1 vector. Transduction with a low-titer SFV-1
vector resulted in low-level gene transfer into growth-
arrested cells (Table 2). This result is comparable to what
is reported with the gene transduction using the HFV
vector in stationary phase cell culture. By increasing
vector titers 100-fold, we were able to enhance transduc-
tion in the arrested populations to similar levels as di-
viding cells. To verify that growth-arrested cells were
stably transduced, the aphidicolin-treated cells were in-
duced to cycle and passaged for several weeks. As
expected, SFV-1 vector transduced cells were main-
tained for 9–12 passages, and the number of b-Gal
ositive cells increased with each passage, though the
ercentage did not increase. In contrast, no b-Gal-posi-
ive cells were observed after the first passage of cells
ransduced with MuLV vector. These results demon-
trated similar transduction efficiencies for SFV-1 in both
ividing and arrested cells regardless of cell type, veri-
ying that simian foamy virus can infect and deliver a
eterologous gene with persistent expression in growth-
rrested cells.
ransduction of postmitotic human neuron cells
To further investigate the utility of SFV-1 vectors in
ondividing cells, transduction efficiency was examined
n terminally differentiated human neuron cells (NT2.N).
T
Transduction Efficiency of SFV-1 and MuLV Vectors in
Cell line Vector
Titer
(31026)a
293T MuLV 0.02
1.0
SFV-1 0.01
1.0
HeLa MuLV 0.02
1.0
SFV-1 0.01
1.0
CRFK MuLV 0.02
1.0
SFV-1 0.01
1.0
a Titers determined on 293T cells and represent number of transduc
b Transduction efficiency in dividing and arrested cells was calculate
of transduction.
c Relative transduction efficiency was calculated as the percent of ar
opulation-stained positive. Results are from three experiments perform
nd MuLV vectors was statistically significant (a 5 0.05).T2.N neurons are functional, post-mitotic human neu-
ons derived from NT2 precursor cells by retinoic acidreatment and differential adhesion. These cells were
ultured as described under Materials and Methods with
final plating on Matrigel basement membrane matrix in
he presence of a mitotic inhibitor. Cells remain termi-
ally differentiated after removal from mitotic inhibition.
ells plated at a density of 1.8 3 105/cm2 were infected
ith either SFV-1 or MuLV vector particles at an m.o.i. of
.5. Assaying for b-Gal activity revealed that 30–50% of
he neuronal cells were positive indicating efficient
ransduction (Fig. 2). Infection of the neurons with MuLV
ector showed 0–,1% transduction efficiency. The SFV-1
ransduced neurons showed b-Gal activity both in cell
bodies and axonal processes (Fig. 2). These results
further established evidence that the SFV-1 vector can
efficiently deliver and express heterologous genes into
nondividing cells independent of the method of cell-cycle
arrest.
Transduction of human peripheral blood
lymphocytes (PBLs)
Development of a vector that can effectively deliver
genes into PBLs is important for gene therapy based
treatment of immune disorders. Simian foamy viruses
have been readily isolated from PBLs of naturally and
experimentally infected animals as well as infected ani-
mal caretakers (Falcone et al., 1999; Heneine et al., 1998;
Hooks and Detrick-Hooks, 1981; Neuman-Haefelin et al.,
1993; von Laer et al., 1996). To test the efficiency of SFV-1
vector in human PBLs, Ficoll gradient purified cells ob-
le Cells in the Presence and Absence of Aphidicolin
Percent transduction efficiency (T.E.)
ividingb Arrestedb Relative T.E.c
4 6 0.2 0.0 6 0.0 0.2 6 0.2
8 6 0.8 0.1 6 0.1 0.2 6 0.1
5 6 0.1 1.5 6 0.1 59.6 6 10.4
0 6 3.7 88.7 6 8.8 98.5 6 26.8
8 6 3.9 0.0 6 0.0 0.1 6 0.1
6 6 4.4 0.7 6 0.3 0.3 6 0.3
3 6 0.1 0.1 6 0.0 11.8 6 5.8
2 6 3.2 12.1 6 4.0 108.8 6 20.0
8 6 3.9 0.0 6 0.0 0.0 6 0.0
0 6 12.5 0.7 6 0.3 0.9 6 0.4
5 6 0.6 1.5 6 0.5 14.8 6 2.8
3 6 15.0 66.3 6 14.8 90.4 6 7.2
rticles/ml as determined by LacZ expression.
al number of LacZ-positive cells divided by total cell population at time
population stained LacZ-positive divided by the percent of proliferating
triplicate. By ANOVA, transduction efficiencies between low-titer SFV-1ABLE 2
Multip
D
3.
90.
2.
90.
8.
48.
0.
11.
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80.
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73.
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restedtained from five different donors were independently
PHA stimulated and infected twice with SFV-1 vector at a
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247SAFE ALTERNATIVE FOR GENE TRANSFER IN CELLSm.o.i. of 1 in 8-h intervals. Gene transduction was deter-
mined by b-Gal assay 72 h p.i. The percentage of trans-
duced PBLs was 87% (Table 3), which is significantly
higher than that of other retroviral vectors (Douglas et al.,
1999; Vandendriessche et al., 1995; Wu et al., 1999; Yang
et al., 1999). Transduction efficiency of human PBLs with
the MuLV vector was ,1%, again consistent with previ-
ous reports of infection of PBLs with equivalent moi
(Culver et al., 1990, 1991; Morgan et al., 1994). In an
attempt to reflect anticipated SFV-1 vector-cell interac-
tion in vivo, we chose to use an experimental culture
system of PBLs and vector infection initiated in an un-
stimulated state. Cells cultured in complete medium in
the presence of 30 U/ml IL-2 without PHA stimulation
were infected with SFV-1 or MuLV vector at the same day
FIG. 2. Transduction of SFV-1 vector in postmitotic human neuron (N
and equal amounts were used to infect NT2 cells. (A) The transductio
and SFV-1 vector infected (right) terminally differentiated NT2 cells. Eac
to form a large cluster composed of several hundred cells. Individual ne
stained blue within the cluster and surrounding it. Large neuritic fasicle
coalesced to form fasicles.
TABLE 3
Transduction of Human Primary Human Peripheral Blood
Lymphocytes by SFV-1 Vector
Cell type
Uninfected
control
MuLV-
amphoa
SFV-1
vectorb
Unstimulated PBLs 0 ,1% 81 6 6.3%
(30 U IL-2 only) (77–90%)
48 hours stimulated PBLs 0 ,1% 87 6 6.0%
(5 mg/ml PHA-P 1 30 U/ml IL-2) (79–94%)
Note. Data are the percent transduction 6 standard error of the
ean for each experiment performed in triplicate. Results shown are
rom independent experiments performed in triplicate with samples
rom three different donors (a) for MuLV and 5 different donors (b) for
SFV-1. Numbers in parentheses indicate range of transduction effi-
ciency among donors. Both MuLV and SFV-1 vectors were titered byt
t
infection of 293T cells and equal amounts were used to infect stimu-
lated and unstimulated PBLs.of cell harvest. FACS analysis of these cells at Day 0 (at
the time vector infection) revealed that 96% were at
G0/G1, 0.39% at S, and 3.61% at G2/M phases of the cell
cycle (Fig. 3). At 72 h, when cells were harvested for
b-Gal assay, the vast majority of the cells were at G0/G1
(94%) of the cell cycle. The percentage of SFV-1 vector
transduction in these unstimulated PBLs was 81% (Table
3). These results indicate that SFV-1 vector can readily
deliver and express transduced genes into both unstimu-
lated and stimulated PBLs, reflecting the usage of the
foamy virus vector for transduction of PBL population
naturally occurring in vivo.
DISCUSSION
In this report, we demonstrate the ability of a SFV-1-
ased vector to mediate efficient transduction of various
rrested and nondividing cell types, including lympho-
ytes and neurons. The SFV-1 vector is capable of gene
ransduction in multiple cell types of different species,
eflecting the wide cell tropism associated with foamy
irus infection in the animal and propagation in cell
ulture. This is a major advantage of foamy virus vectors.
urthermore, we have shown that lymphocytes and neu-
ons that are critical for gene transfer in vivo can be
nfected with SFV-1 vector. These experiments ascertain
he potential use of SFV vectors in critical cellular targets
n vivo.
Not only have we demonstrated that an SFV-1 vector
an transduce fibroblast cell lines from different species,
nd human cell lines of epithelial, lymphoid, and hema-
opoietic origins, but we also have shown that transduc-
s. Both MuLV and SFV-1 vectors were titered by infection of 293T cells
encies of SFV-1 and MuLV vectors are presented. (B) Uninfected (left)
l represents a pure population of NT2 neurons, which have aggregated
re visible around the edge of the large central cluster and are densely
d from the cluster and represent multiple individual neurites that haveT2) cell
n effici
h pane
urons aion in all cells is similar. This suggests that cell recep-
ors for primate foamy viruses are expressed at compa-
d
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248 MERGIA ET AL.rable levels on several cell types from different species.
Whether the receptor is a protein or another class of
cell-surface molecules is not known. Other retroviral vec-
tors require pseudotyping the envelope protein with
other viruses in order to broaden cell tropism. This notion
may make these vectors cumbersome to utilize as a
vehicle to deliver genes in vivo. Since foamy viruses
emonstrate naturally broad tissue tropism (Hooks and
etrick-Hooks, 1981; Neuman-Haefelin et al., 1993),
SFV-1 vector may be an ideal gene-delivery system.
Previously, it was reported that foamy viruses failed
to replicate in cells that were arrested in the G1/S
phase of the cell cycle by aphidicolin treatment (Bie-
niasz et al., 1995), although others have shown HFV
replication in stationary phase cells (Bieniasz et al.,
1995). Our results showed that SFV-1 vector particles
can indeed transduce and express transgenes in
growth-arrested and postmitotic cells. The efficiency
of transduction in these arrested cells is equivalent to
that of lentivirus vectors (Klimatcheva et al., 1999;
FIG. 3. Cell-cycle analysis of PHA-stimulated and -unstimulated huma
s percent of total population. FACS analyses were performed at the tim
ransduction by b-Gal assay. Vector infection was carried out at Day 0 (
of cell activation) for stimulated cells. Cells were stained for b-Gal 72
remained .94%, while cells progressing through the S to G2/M was ,
of cells progressing through the S phase from 0.4% at day of isolationNaldini et al., 1996; Poeschla et al., 1998a,b). In addi-
ion, transduction efficiency (30–50%) of postmitotic
p
fuman neurons exceeds that of HIV-1 basal vectors
Klimatcheva et al., 1999; Naldini et al., 1996; Poeschla
et al., 1998a,b), emphasizing the potential utility of
SFV-1 vector in nondividing cells in vivo. In foamy virus
nfection of G1/S arrested cells, nuclear import of the
reintegration complex allows translocation of the ge-
ome into the nucleus (Saib et al., 1997). This obser-
vation is in support of our finding that noncycling cells
can be transduced with the SFV-1 vector. Previous
studies showed that, despite nuclear transport of the
genome, no 59 foamy virus LTR-driven gene expres-
sion was observed in growth-arrested cells (Saib et
al., 1997). However, our transgene expression is sup-
ported by a CMV promoter, which is active in many
growth-arrested cells (Klimatcheva et al., 1999; Naldini
et al., 1996; Poeschla et al., 1998a,b). It is possible that
he foamy virus promoters may not be effective in
rowth-arrested cells, thereby limiting gene expres-
ion. Furthermore, by increasing vector titers 100-fold,
e were able to enhance transduction in the arrested
. The populations of cells at different phases of the cell cycle are given
1 vector infection and when cell were harvested to determine for LacZ
iately following isolation) for unstimulated cells and at 48 h (at the time
On all days, the numbers of cells of the unstimulated cells at G0/G1
contrasts, stimulated cells showed a dramatic increase in the number
after 48 h of PHA-stimulation.n PBLs
e SFV-
immed
h p.i.opulations to similar levels as dividing cells. There-
ore, the reason for the higher transduction efficiency
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249SAFE ALTERNATIVE FOR GENE TRANSFER IN CELLSin comparison to previous studies with HFV vector
(Russell and Miller, 1996) is in part due to our high-titer
SFV-1 vector.
Human PBLs are primary targets for gene therapy of
inherited and acquired disorders of the immune system.
Development of a gene-transfer system that warrants
efficient transduction of human PBLs is critical for vari-
ous applications in gene therapy. The high efficiency of
PBL transduction by SFV-1 vector is a major advantage.
In contrast, MuLV-mediated gene transfer into primary
lymphocytes is generally low (,10%) when a low m.o.i. of
vector is used (Culver et al., 1990, 1991; Morgan et al.,
994). Consistent with these previous reports, we have
lso observed ,1% transduction when human PBLs
ere infected with MuLV vector particles at an m.o.i. of 1.
his low-level infection is attributed to MuLV’s ineffi-
iency at transducing nondividing cells and restricted
eplication in human PBLs despite entry (Naldini et al.,
996; Woffendin et al., 1994). A higher transduction effi-
iency ranging from 20 to 50% in human primary lympho-
ytes has been accomplished with MuLV vectors only
fter enhancing vector titers by pseudotyping with vesic-
lar stomtitis virus envelope glycoprotein G (VSV-G) and
mproving the method of infections with complex manip-
lations of the system (Burns et al., 1993; Pollok et al.,
1998; Sharma et al., 1996; Vandendriessche et al., 1995;
Wu et al., 1999; Yang et al., 1999).
HIV-based vectors also have some significant limita-
tions. Since HIV infects CD4-positive cells and nondivid-
ing cells, HIV-based vectors were thought to be poten-
tially efficient in primary lymphoid cells (Fauci, 1996;
Lewis et al., 1992; Spina et al., 1995; von Schwedler et al.,
1994; Weinberg et al., 1991). However, low transduction
efficiency is also associated with HIV vectors, although
transduction efficiency of HIV vectors can be increased
several-fold by psuedotyping with VSV-G and subse-
quent concentration procedures (Akkina et al., 1996; Nal-
dini et al., 1996). Recently, transduction efficiency #60%
of activated human PBLs was observed with VSV-G
pseudotyped HIV vector (Douglas et al., 1999). However,
we have demonstrated gene transfer with an SFV-1 vec-
tor in both PHA-stimulated and -unstimulated PBLs
.80% with infection at a significantly lower m.o.i. and
without any manipulation of the vector system. This level
of vector transduction by SFV-1 is higher than that re-
ported for any other retroviral vector. The reason for the
high efficiency of SFV-1 vector may have to do with the
distinct mechanisms of virus replication. Reverse tran-
scription occurs late in the foamy virus replication before
the virion is released from the infected cells, and ;20%
of virion contain fully reverse transcribed DNA (Moebes
et al., 1997; Yu et al., 1996; Yu et al., 1999). In cases where
the barrier for gene transfer is at the point of reverse
transcription, foamy virus has an advantage since 20% of
the virus particles contain fully reverse transcribed DNA
genome that is infectious. A low pool of nucleotides
t
pavailable for reverse transcription in unstimulated lym-
phocytes following lentivirus vector infection could affect
the efficiency of gene transfer (Korin and Zack, 1998;
Unutmaz et al., 1999; Zack et al., 1990). Thus, an SFV-1
based-vector will be able to provide a highly efficient
method for clinical gene transfer into primary human
PBLs. Furthermore, since no disease is associated with
foamy viruses, the SFV-1 vector system may prove to be
a safe delivery vehicle for human gene therapy than
currently utilized vectors. The constructions of SFV-1
vectors and packaging DNAs with minimal genome se-
quences are in progress to improve the potential utility of
the foamy virus vector system in clinical application.
MATERIALS AND METHODS
Cell culture
Cell lines 293 and 293T (human kidney fibroblasts),
HeLa (human epithelial cell), HuT 78 (human T cell), K562
(human hematopoietic cell), NT2 (NTera2C1.D1, human
neurons), Cos-7 (African green monkey kidney fibro-
blasts), CRFK (Crandell feline kidney fibroblasts), and
murine L929 (murine fibroblasts) were obtained from
American Type Culture Collection (Rockville, MD).
HOS.CD4/CCR5 and HOS.CD4/CXCR4 cell lines (human
osteosarcoma) were made available by the AIDS Re-
search and Reference Reagent Program, Division of
AIDS, NAIAD, NIH. All fibroblast (except CRFK cells), NT2
cells, and HeLa cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal
calf serum (FCS). CRFK cells were cultured in minimal
essential media (MEM) supplemented with 1% nones-
sential amino acids and 10% fetal horse serum (FHS).
HuT78 were maintained in RPMI medium containing 10%
FCS. K562 were propagated in Iscove’s modified DMEM
supplemented with 4 mM L-glutamine and 10% FCS.
OS.CD4/CCR5 and HOS.CD4/CXCR4 cell lines were
ultured in DMEM, 2.5 mM HEPES, 10% FBS, and 1
mg/ml puromycin.
Plasmids
Construction of the recombinant SFV-1 packaging
plasmid (pCGPETH) and vector plasmid (pCV7-9) were
described previously (Wu and Mergia, 1999). The pCG-
PETH plasmid contains the SFV-1 gag, pol, env, and tas
genes under the transcriptional control of the human
cytomegalovirus immediate early (CMV-IE) gene pro-
moter, and simian virus 40 (SV40) polyA additional signal
sequence (Fig. 1). The pCV7-9 plasmid contains SFV-1
sequences extending from the R region of the 59 LTR to
the 39 end of pol (nucleotide positions 1170–7080) and
equences extending from the orf-2 region upstream
rom the polypurine tract at the 39 end of the genome to
he 39LTR (nucleotide positions 10,749–12,972). CMV-IE
romoter was fused to the R region to initiate transcrip-
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pCV7-9 also contains the lacZ marker gene under the
transcriptional control of the human CMV-IE promoter
inserted between the end of pol gene and the 39 SFV-1
segment. The MuLV vector system plasmids, pCLampho
(packaging plasmid) and pCLMFG-lacZ (MuLV vector
containing the Lac-Z gene), were gifts from Inder M.
Verma of the Salk Institute, San Diego, CA.
Transfections and production of packaged vectors
Transfections of 293T cells were carried out in six-well
plates by the liposome-mediated method with the re-
agent LipofectAMINE according to manufacturer’s rec-
ommendations (Life Technologies, Inc., Gaithersburg,
MD). Cells were seeded at a density of 4.5 3 105 in
ix-well plates and co-transfected with 1–2 mg of each
CV7-9 and pCGPETH plasmids or pCLampho and
CLMFG-lacZ. To enhance foamy virus vector produc-
ion, cells were stimulated the next day with 10 mM
odium butyrate (Sigma) for 12 h and supernatants were
arvested at Day 3 or 4 post-transfection. The amounts
f SFV-1 vectors produced were titered on fresh 293T
ells plated at a density of 2.5 3 104 in 24-well plates.
Forty-eight hours after infection, cells were stained for
b-galactosidase (b-Gal) activity. Briefly, cells were
washed twice in phosphate-buffered saline (PBS), then
fixed with 0.05% glutaraldehyde in PBS. Cells were
washed in PBS an additional three times and incubated
in 5-bromo-4-chloro-3-indolyl-b-D-galactopyransoside (X-
gal) for a minimum of 4 h. Cultures were monitored under
phase contrast microscopy for appearance of blue stain-
ing, and positive cells were scored.
Cell growth arrest and flow cytometry analysis
Cells were treated with aphidicolin to arrest them at
G1/S phase of the cell cycle. Hela, 293T, and CRFK cell
lines, were incubated with varying amounts of aphidico-
lin and pulsed with 3H-thymidine for 18 h to initially
etermine the concentration of aphidicolin to prevent
NA replication. Aphidicolin concentrations resulting in
5% 3H-uptake in comparison to normally growing cul-
tures were used for further cell-cycle-arrest studies.
HeLa, 293T, and CRFK were treated with 20 mg/ml
phidicolin, as described previously (Lewis and Emer-
an, 1994; Olsen, 1998; Poeschla et al., 1998b; Springett
t al., 1989), prior to infection with SFV-1 vectors and
eplenished daily until staining for b-Gal activity. Cell-
cycle arrest with aphidicolin was verified at 24 h and 72 h
by flow cytometry for DNA content by propidium iodide
staining as described previously (Vindolv and Chris-
tensen, 1990).
Postmitotic human neuronsNT2N human neurons were prepared as previously
described (Pleasure et al., 1992). Briefly, NTera 2 cells Bwere differentiated to neurons (NT2N) by culturing (3.2 3
103 cells/cm2) in the presence of 10 mM all-trans retinoic
cid for 5 weeks followed by replating at 1:6 density
ithout retinoic acid in the presence of mitotic inhibitors
10 mM 5-fluoro-29-deoxyuridine, 10 mM uridine, 1 mM
ytosine-a-D-arabinose furanoside). One week later, a
inal replating was done using culture vessels coated
ith Matrigel (Collaborative Biomedical Products, Bed-
ord, MA) without mitotic inhibitors. Postmitotic NT2N
eurons were cultured at a density of 1.8 3 105 cells/cm2
and were inoculated with SFV-1 or MuLV vector at a
m.o.i. of 2.5 in 10% FBS/DMEM. After 72 h, cultures were
washed (PBS), fixed with 1% formaldehyde and 0.2%
glutaraldehyde (in PBS) for 5 min at room temperature,
washed, and stained for b-Gal activity.
Primary peripheral blood lymphocytes
Human peripheral blood lymphocytes (PBLs) were iso-
lated by Ficoll-Hypaque density gradient centrifugation.
Adherent cells were removed by plating gradient-purified
samples and harvesting suspension cells. PBLs were
maintained in RPMI 1640 with 10% FBS and 30 U/ml
interleukin 2 (IL-2). Cells were infected with MuLV or
SFV-1 vector at the same day of isolation or stimulated
with 5 mg/ml phytohemagglutanin (PHA-P, Difco) for 48 h
rior to vector infection. Cells were seeded in 24-well
lates (5 3 105 per well), centrifuged at room tempera-
ture for 10 min at 2500 rpm, and resuspended in 300 ml
moi of 1) of retroviral supernatants. The resuspended
ells were then spun at 1500 rpm for 1 h as described
reviously (Bahner et al., 1996; Bunnell et al., 1995). The
infection procedure was repeated 8 h later, and cells
were stained for b-Gal activity 72 h after infection.
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